این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
چهارشنبه 19 آذر 1404
Iranian Journal of Basic Medical Sciences
، جلد ۲۰، شماره ۵، صفحات ۴۷۴-۴۸۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
Effect of rosiglitazone on amyloid precursor protein processing and Aβ clearance in streptozotocin-induced rat model of Alzheimer’s disease
چکیده انگلیسی مقاله
Objective(s): Increasing evidence suggests that Alzheimer's disease (AD) is associated with diabetes. Rosiglitazone, a peroxisome proliferator-activated receptor γ (PPAR-γ) agonist and anti-diabetic agent, may improve symptoms of AD. However, the underlying therapeutic potential of it has not been fully elucidated. Materials and Methods: Rats were divided into four groups: control group, sham operated group, Streptozotocin (STZ) group, rosiglitazone (RGZ) group. Particularly, the STZ-induced rat model was established by intracerebroventricular injection (3 mg/kg) on the first and third day. The water maze behavioral test was performed to evaluate spatial reference learning and memory of the rats. Aβ1-40 and Aβ1-42 levels were measured by ELISA method. To determine APP-derived fragment, BACE1 and Aβ degrading enzymes levels, such as NEP and IDE, as well as Aβ transportation protein level, such as LRP1, RAGE, Abca1 and APOE , which were analyzed by Western blot. Immunohistochemistry was used to observe the change of Aβ1-40 and Aβ1-42 in hippocampus. Results: Chronic treatment with RGZ could reduce the Aβ level and improved spatial memory performance in STZ-induced rat model. However, RGZ modified the expression of specific transport proteins monitoring Aβ clearance, such as ATP-binding cassette transporter 1 (ABCA1), lipoprotein receptor-related protein 1 (LRP1), and the advanced glycation end product-specific receptor (RAGE) rather than change levels of Aβ degrading enzymes, such as IDE and NEP, nor affect APP processing. Conclusion: As a potential therapeutic strategy, rosiglitazone might exert anti-AD effect not by alteration of APP processing pathway and Aβ degradation directly, but through promotion of Aβ clearance indeed.
کلیدواژههای انگلیسی مقاله
نویسندگان مقاله
li ونگ | li wang
department of geriatrics, the second affiliated hospital of the harbin medical university, harbin 150081, china
wei liu | wei liu
department of neurology, peking university third hospital, beijing 100080, china
ying فان | ying fan
department of geriatrics, the second affiliated hospital of the harbin medical university, harbin 150081, china
tingting liu | tingting liu
department of geriatrics, the second affiliated hospital of the harbin medical university, harbin 150081, china
chunjiang yu | chunjiang yu
department of neurology, the second affiliated hospital of the harbin medical university, harbin 150081, china
نشانی اینترنتی
http://ijbms.mums.ac.ir/article_8669.html
فایل مقاله
دریافت فایل مقاله
کد مقاله (doi)
زبان مقاله منتشر شده
en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
Original Article
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات